Reldesemtiv
As of the edition of 20 October 2026, Reldesemtiv is a small molecule: stopped in 2023; acts on TNNC2, TNNI2 and TNNT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 6, 3 stopped early
- Disease areas
- Nervous system; Nutrition and metabolism; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 3 | 3 | 0 | 0 |
| Phase 3 | 2 | 0 | 0 | 2 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cytokinetics | Lead sponsor of trials | 2016 to now |
| Astellas | Lead sponsor of trials | 2016 to now |